.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
McKesson
McKinsey
Cerilliant
AstraZeneca
UBS
Accenture
Express Scripts
Colorcon
Chubb

Generated: September 19, 2017

DrugPatentWatch Database Preview

Doxylamine succinate; pyridoxine hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for doxylamine succinate; pyridoxine hydrochloride and what is the scope of doxylamine succinate; pyridoxine hydrochloride freedom to operate?

Doxylamine succinate; pyridoxine hydrochloride
is the generic ingredient in four branded drugs marketed by Actavis Labs Fl Inc, Duchesnay, and Sanofi Aventis Us, and is included in four NDAs. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Doxylamine succinate; pyridoxine hydrochloride has ninety-two patent family members in forty-two countries.

There are fourteen drug master file entries for doxylamine succinate; pyridoxine hydrochloride. One supplier is listed for this compound.

Summary for Generic Name: doxylamine succinate; pyridoxine hydrochloride

Tradenames:4
Patents:5
Applicants:3
NDAs:4
Drug Master File Entries: see list14
Suppliers / Packagers: see list1
Clinical Trials: see list2,473
Drug Prices:see low prices
DailyMed Link:doxylamine succinate; pyridoxine hydrochloride at DailyMed

Pharmacology for Ingredient: doxylamine succinate; pyridoxine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Duchesnay
BONJESTA
doxylamine succinate; pyridoxine hydrochloride
TABLET, EXTENDED RELEASE;ORAL209661-001Nov 7, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Duchesnay
DICLEGIS
doxylamine succinate; pyridoxine hydrochloride
TABLET, DELAYED RELEASE;ORAL021876-001Apr 8, 2013ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Duchesnay
DICLEGIS
doxylamine succinate; pyridoxine hydrochloride
TABLET, DELAYED RELEASE;ORAL021876-001Apr 8, 2013ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Actavis Labs Fl Inc
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE
doxylamine succinate; pyridoxine hydrochloride
TABLET, DELAYED RELEASE;ORAL205811-001Aug 19, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Duchesnay
BONJESTA
doxylamine succinate; pyridoxine hydrochloride
TABLET, EXTENDED RELEASE;ORAL209661-001Nov 7, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Duchesnay
BONJESTA
doxylamine succinate; pyridoxine hydrochloride
TABLET, EXTENDED RELEASE;ORAL209661-001Nov 7, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Sanofi Aventis Us
BENDECTIN
doxylamine succinate; pyridoxine hydrochloride
TABLET, EXTENDED RELEASE;ORAL010598-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Duchesnay
BONJESTA
doxylamine succinate; pyridoxine hydrochloride
TABLET, EXTENDED RELEASE;ORAL209661-001Nov 7, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: doxylamine succinate; pyridoxine hydrochloride

Country Document Number Estimated Expiration
Denmark1397133► Subscribe
Japan2004521146► Subscribe
Denmark200200947► Subscribe
Hungary227003► Subscribe
Philippines12017500282► Subscribe
Hong Kong1052654► Subscribe
Israel150349► Subscribe
Uruguay27352► Subscribe
World Intellectual Property Organization (WIPO)2013123595► Subscribe
Canada2920247► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Mallinckrodt
Cipla
US Department of Justice
US Army
Medtronic
Express Scripts
UBS
McKesson
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot